Significant improvement in melanoma survival over the last decade: A Hungarian nationwide study between 2011 and 2019.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
18
10
2022
accepted:
02
02
2023
medline:
17
4
2023
pubmed:
15
2
2023
entrez:
14
2
2023
Statut:
ppublish
Résumé
Recent real-world studies have reported significant improvements in the survival of malignant melanoma in the past few years, mainly as a result of modern therapies. However, long-term survival data from Central Eastern European countries such as Hungary are currently lacking. This nationwide, retrospective study examined melanoma survival in Hungary between 2011-2019 using the databases of the National Health Insurance Fund (NHIF) and Central Statistical Office (CSO) of Hungary. Crude overall survival and age-standardized 5-year net survival as well as the association between age, sex and survival were calculated. Between 2011 and 2019, 22,948 newly diagnosed malignant melanoma cases were recorded in the NHIF database (47.89% male, mean age: 60.75 years (SD: ±16.39)). Five-year overall survival was 75.40% (women: 80.78%; men: 69.52%). Patients diagnosed between 2017-2019 had a 20% lower risk of mortality compared to patients diagnosed between 2011-2012 (HR 0.80, 95% CI 0.73-0.89; p < 0.0001). Age-standardized 5-year net survival rates in 2011-2014 and 2015-2019 were 90.6% and 95.8%, respectively (women: 93.1% and 98.4%, men: 87.8% and 92.7%, respectively). The highest age-standardized 5-year net survival rates were found in the 0-39 age cohort (94.6% in the 2015-2019 period). Hungary has similar melanoma survival rates to Western European countries. Based on net survival, the risk of dying of melanoma within 5 years was cut by more than half (55%) during the study period, which coincides with the successful implementation of awareness campaigns and the wide availability of modern therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Recent real-world studies have reported significant improvements in the survival of malignant melanoma in the past few years, mainly as a result of modern therapies. However, long-term survival data from Central Eastern European countries such as Hungary are currently lacking.
METHODS
METHODS
This nationwide, retrospective study examined melanoma survival in Hungary between 2011-2019 using the databases of the National Health Insurance Fund (NHIF) and Central Statistical Office (CSO) of Hungary. Crude overall survival and age-standardized 5-year net survival as well as the association between age, sex and survival were calculated.
RESULTS
RESULTS
Between 2011 and 2019, 22,948 newly diagnosed malignant melanoma cases were recorded in the NHIF database (47.89% male, mean age: 60.75 years (SD: ±16.39)). Five-year overall survival was 75.40% (women: 80.78%; men: 69.52%). Patients diagnosed between 2017-2019 had a 20% lower risk of mortality compared to patients diagnosed between 2011-2012 (HR 0.80, 95% CI 0.73-0.89; p < 0.0001). Age-standardized 5-year net survival rates in 2011-2014 and 2015-2019 were 90.6% and 95.8%, respectively (women: 93.1% and 98.4%, men: 87.8% and 92.7%, respectively). The highest age-standardized 5-year net survival rates were found in the 0-39 age cohort (94.6% in the 2015-2019 period).
CONCLUSION
CONCLUSIONS
Hungary has similar melanoma survival rates to Western European countries. Based on net survival, the risk of dying of melanoma within 5 years was cut by more than half (55%) during the study period, which coincides with the successful implementation of awareness campaigns and the wide availability of modern therapies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
932-940Subventions
Organisme : MSD Pharma Hungary Ltd.
Organisme : MSD Pharma Hungary Ltd
Organisme : National Tumor Biology Laboratory
ID : 2022-2.1.1-NL-2022-00010
Organisme : the Hungarian Thematic Excellence Program
ID : TKP2021-EGA-44
Informations de copyright
© 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg. 2007;60(1):32-40.
Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355(1):51-65.
Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Pukkala E, et al. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol. 2014;28(9):1170-8.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol. 2016;136(6):1161-71.
Liszkay G, Kiss Z, Gyulai R, Oláh J, Holló P, Emri G, et al. Changing trends in melanoma incidence and decreasing melanoma mortality in Hungary between 2011 and 2019: a Nationwide epidemiological study. Front Oncol. 2021;10:612459.
Guy P, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC. Centers for Disease Control and Prevention (CDC). Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030. MWR Morb Mortal Wkly Rep. 2015;64(21):591-6.
Elder DE, Gimotty PA, Guerry D. Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features. Dermatol Ther. 2005;18(5):369-85.
Schuchter L, Schultz DJ, Synnestvedt M, Trock BJ, Guerry D, Elder DE, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. The pigmented lesion group. Ann Intern Med. 1996;125(5):369-75.
Behbahani S, Maddukuri S, Cadwell JB, Lambert WC, Schwartz RA. Gender differences in cutaneous melanoma: demographics, prognostic factors, and survival outcomes. Dermatol Ther. 2020;33(6):e14131. https://doi.org/10.1111/dth.14131
de Vries E, Nijsten TE, Visser O, Bastiaannet E, van Hattem S, Janssen-Heijnen ML, et al. Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol. 2008;19(3):583-9.
Forsea AM, Del Marmol V, de Vries E, Bailey EE, Geller AC. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol. 2012;167(5):1124-30.
Barbaric J, Sekerija M, Agius D, Coza D, Dimitrova N, Demetriou A, et al. Disparities in melanoma incidence and mortality in South-Eastern Europe: increasing incidence and divergent mortality patterns. Is progress around the corner? Eur J Cancer. 2016;55:47-55.
Donia M, Ellebaek E, Øllegaard TH, Duval L, Aaby JB, Hoejberg L, et al. The real-world impact of modern treatments on the survival of patients with metastatic melanoma. Eur J Cancer. 2019;108:25-32.
Cowey CL, Liu FX, Boyd M, Aguilar KM, Krepler C. Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: a retrospective, community oncology-based cohort study (a STROBE-compliant article). Medicine (Baltimore). 2019;98(28):e16328.
Uprety D, Bista A, Chennamadhavuni A, Niroula A, Jafri SIM, Smith A, et al. Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study. Melanoma Res. 2018;28(1):56-60.
Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463-82.
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-75.
Gutiérrez-González E, López-Abente G, Aragonés N, Pollán M, Pastor-Barriuso R, Sánchez MJ, et al. Trends in mortality from cutaneous malignant melanoma in Spain (1982-2016): sex-specific age-cohort-period effects. J Eur Acad Dermatol Venereol. 2019;33(8):1522-8.
Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunol Immunother. 2018;67(12):1833-44.
Berk-Krauss J, Stein JA, Weber J, Polsky D, Geller AC. New systematic therapies and trends in cutaneous melanoma deaths among US whites, 1986-2016. Am J Public Health. 2020;110(5):731-3.
Brunssen A, Waldmann A, Eisemann N, Katalinic A. Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: a systematic review. J Am Acad Dermatol. 2017;76(1):129-139.e10.
Iannacone MR, Green AC. Towards skin cancer prevention and early detection: evolution of skin cancer awareness campaigns in Australia. Melanoma Manag. 2014;1(1):75-84.
Youl PH, Soyer HP, Baade PD, Marshall AL, Finch L, Janda M. Can skin cancer prevention and early detection be improved via mobile phone text messaging? A randomised, attention control trial. Prev Med. 2015;71:50-6.
Tabbakh T, Volkov A, Wakefield M, Dobbinson S. Implementation of the SunSmart program and population sun protection behaviour in Melbourne, Australia: results from cross-sectional summer surveys from 1987 to 2017. PLoS Med. 2019;16(10):e1002932.
del Marmol V, de Vries E, van der Endt J, Roseeuw D, Vandaele M, Pirard C, et al. Evaluation of 7 years of Euromelanoma day, a voluntary melanoma screening campaign in Belgium. Melanoma Res. 2006;16:S22-3.
Suppa M, Altomare G, Cannavò SP, Capizzi R, Catricalà C, Colombo E, et al. The Italian Euromelanoma day: evaluation of results and implications for future prevention campaigns. Int J Dermatol. 2014;53(6):699-706.
Ócsai H, Ócsai H, Battyáni Z, Emri G, Liszkay G, Somlai B, et al. EuroMelanoma Nappal szerzett tapasztalataink az elmúlt 5 évben (2009-2013). Magyar Onkológia. 2013;57(5):68.
Hungarian regulation: 60/2003 ESZCSM rendelet az egészségügyi szolgáltatások nyújtásához szükséges szakmai minimumfeltételekről [Regulation on the professional minimum requirements on providing health care].
Regulation on certain questions of social insurance financing of health care services: (9/1993). (IV. 2.) NM rendelet az egészségügyi szakellátás társadalombiztosítási finanszírozásának egyes kérdéseiről [Regulation on certain questions of social insurance financing of health care services].
Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, et al. Access to innovative medicines for metastatic melanoma worldwide: melanoma world society and European Association of Dermato-oncology survey in 34 countries. Eur J Cancer. 2018;104:201-9.
Balatoni T, Liszkay G, Miklós Z, Kásler M. A melanoma malignum epidemiológiája (Klinikai tapasztalatok az Országos Onkológiai Intézetben) [epidemiology of malignant melanoma (clinical experience at the National Institute of oncology in Hungary)]. Orv Hetil. 2011;152(25):1000-6. https://doi.org/10.1556/OH.2011.29148
Wróbel S, Przybyło M, Stępień E. The clinical trial landscape for melanoma therapies. J Clin Med. 2019;8(3):368. https://doi.org/10.3390/jcm8030368
Liszkay G. Klinikai vizsgálatok eredményei és törzskönyvezett gyógyszerek az elõrehaladott melanoma immunterápiájában [Clinical studies and accepted therapies of advanced melanoma]. Magy Onkol. 2016;60(1):11-5. Hungarian.
Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, et al. Gender-related differences in outcome for melanoma patients. Ann Surg. 2006;243(5):693-8. discussion 698-700.
Cancer Research UK. Melanoma skin cancer survival statistics. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer/survival#heading-Two. Accessed 30 March 2021.
Hieken TJ, Glasgow AE, Enninga EAL, Kottschade LA, Dronca RS, Markovic SN, et al. Sex-based differences in melanoma survival in a contemporary patient cohort. J Womens Health (Larchmt). 2020;29(9):1160-7.
Liu W, Dowling JP, Murray WK, McArthur GA, Thompson JF, Wolfe R, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol. 2006;142(12):1551-8.
Joosse A, de Vries E, Eckel R, Nijsten T, Eggermont AM, Hölzel D, et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol. 2011;131(3):719-26.
Bellenghi M, Puglisi R, Pontecorvi G, De Feo A, Carè A, Mattia G. Sex and gender disparities in melanoma. Cancers (Basel). 2020;12(7):1819. https://doi.org/10.3390/cancers12071819
Várnai M, Kiss Z, Gyulai R, Oláh J, Holló P, Emri G, et al. Improving quality indicator of melanoma management - change of melanoma mortality-to-incidence rate ratio based on a Hungarian Nationwide retrospective study. Front Oncol. 2021;11:745550.
Plym A, Ullenhag GJ, Breivald M, Lambe M, Berglund A. Clinical characteristics, management and survival in young adults diagnosed with malignant melanoma: a population-based cohort study. Acta Oncol. 2014;53(5):688-96.
Cancer Research UK. Melanoma skin cancer survival statistics. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer/survival#heading-One. Accessed 31 March 2021.
Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, et al. Malignant melanoma in the elderly: different regional disease and poorer prognosis. J Cancer. 2011;2:538-43.
Kruijff S, Bastiaannet E, Francken AB, Schaapveld M, van der Aa M, Hoekstra HJ. Breslow thickness in The Netherlands: a population-based study of 40 880 patients comparing young and elderly patients. Br J Cancer. 2012;107(3):570-4.
Ciocan D, Barbe C, Aubin F, Granel-Brocard F, Lipsker D, Velten M, et al. Distinctive features of melanoma and its management in elderly patients: a population-based study in France. JAMA Dermatol. 2013;149(10):1150-7.
Tsai S, Balch C, Lange J. Epidemiology and treatment of melanoma in elderly patients. Nat Rev Clin Oncol. 2010;7(3):148-52.
Global Dat Lab website - Hungarian HDI data from 2011 to 2019. [last update: 09.01.2023]. Available from: https://globaldatalab.org/shdi/table/shdi/HUN/?levels=1+4&interpolation=0&extrapolation=0
Shen W, Sakamoto N, Yang L. Melanoma-specific mortality and competing mortality in patients with non-metastatic malignant melanoma: a population-based analysis. BMC Cancer. 2016;16:413. https://doi.org/10.1186/s12885-016-2438-3